Profusa shares surge 13.3% premarket as Lumee tissue oxygen system launches for $47.9B CRO market with immediate service revenue.

Profusa (PFSA) surged 13.30% in premarket trading following the launch of its Lumee tissue oxygen Healthcare Research offerings, targeting the $47.9B CRO market. The company announced immediate commercial availability of research-use-only kits and a service-enabled platform, enabling rapid deployment for contract research organizations. The initiative, led by newly appointed Head of Government and Healthcare Research Business Sean Givens, aims to generate near-term service revenue by providing real-time tissue oxygenation data for drug development applications. With the CRO market projected to grow at a 7% CAGR to $91.2B by 2034, Profusa highlighted the strategic alignment with industry demand for advanced biosensing technologies to enhance R&D efficiency. The product launch, coupled with leadership expertise and validated sensor technology, underscored investor optimism about the company’s ability to capture a share of the expanding pharmaceutical services sector.